MEDIROM Group Reports Q1 2026 Results
TOKYO, May 28, 2026 (GLOBE NEWSWIRE) -- This report presents an overview of our business performance and key performance indicators...
COVID-19
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent...
EOM Pharmaceutical Holdings Reports FDA Clearance of an IND for a Clinical Trial in Cachectic Cancer Patients
MONTVALE, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”, the “Company”) an innovative clinical-stage...
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed GAITHERSBURG, Md., May...
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious...
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more...
Ebola Global Health Emergency Needs a Broad-Spectrum Drug – NV-387 is a Strong Potential Candidate, Says NanoViricides
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
NanoViricides, Inc. Has Filed its Quarterly Report – NV-387 Advancing for Phase II
SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has...
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
Professor Casper H.J. van Eijck, MD, PhD Professor Casper H.J. van Eijck, MD, PhD, Professor and Pancreato-biliary Surgeon at Erasmus...
Adagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming...
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit...
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin Robert P....
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its...
ISM® Honors Farryn Melton with 2026 J. Shipman Gold Medal Award
Former Fortune 100 chief procurement officer recognized for leadership that strengthened the supply chain profession and the people who power...
Nanox Signs Distribution Agreement with Radiology Oncology Systems to Expand Nanox.ARC Adoption in the United States
Expands Nanox’s growing network of U.S. distribution partnerships PETAH TIKVA, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd....
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will...
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will...
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will...